HER2 testing results, practices, and preferences among pathologists and oncologists in the US community setting: a mixed-methods study
While innovative testing tools were viewed favorably by pathologists and oncologists, cost and need for training were barriers to adoption. Improving documentation practices, standardizing protocols, and adopting tools such as digital pathology could enhance the accuracy and consistency of HER2 testing.
Authors
- Clara Lam (ORCID: https://orcid.org/0009-0000-8995-2697)
- Angel F. Valladares (ORCID: https://orcid.org/0000-0001-6437-435X)
- Marija Tesic-Schnell
- Simone Treiger Sredni (ORCID: https://orcid.org/0000-0002-1715-3885)
- Miriam Joan Haviland (ORCID: https://orcid.org/0000-0003-3553-6561)
- Zakiya Haji-Noor (ORCID: https://orcid.org/0000-0002-0258-2230)
- Edward Espinal-Domínguez
- John Cochran
- Simon M. Collin (ORCID: https://orcid.org/0000-0002-1239-1681)
- Lisa Okazaki
Institutions
- IQVIA (United Kingdom) (GB)
- AstraZeneca (France) (FR)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Finland) (FI)
- IQ Solutions (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1007/s10549-025-07832-1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Daiichi Sankyo Europe